Oussama Grari

Dr. Oussama Grari

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2025 in The Microbe
Verified
Journal Article
Open access
OGOussama Grari
Oussama Grari
SESaid Ezrari
Said Ezrari
IYImane El Yandouzi
Imane El Yandouzi
EBElmostapha Benaissa
Elmostapha Benaissa
YLYassine Ben Lahlou
Yassine Ben Lahlou
AMAdil MALEB
Adil MALEB

1 January 2024 in Journal of Medical Biochemistry
Verified
Journal Article
Open access
PDF file
OGOussama Grari
Oussama Grari
AHAmina Himri
Amina Himri
NDNisma Douzi
Nisma Douzi
SBSoufiane Beyyoudh
Soufiane Beyyoudh
IEImad-Eddine Elkhamlichi
Imad-Eddine Elkhamlichi
MCMohammed Choukri
Mohammed Choukri
Background: The precision of test measurements is critical in clinical diagnostics, especially for biomarkers like total PSA and homocysteine, which are essential to disease assessment. Using the CMIA approach, this study investigates the repeatability and reproducibility of these biomarkers on the Abbott Alinity system. Methods: The present study was conducted in the clinical chemistry laboratory at Mohammed VI University Hospital of Oujda. The evaluation of the Alinity i-system's analytical performance for total PSA and homocysteine focused on assessing repeatability and intermediate precision. The assessment followed the protocols and guidelines established by the French Accreditation Committee (COFRAC). Results: Our analysis yielded favorable findings regarding the performance of the Alinity assays. The coefficients of variation for both the within-run and between-run precision were less than 5.89% and 4.29%, respectively. These findings produce acceptable outcomes compared to the manufacturer's claims and the SFBC database. Our study underscores the tests' precision, affirming the CMIA method's reliability in measuring total PSA and homocysteine levels. Conclusions: The assessment of the Alinity i-system for total PSA and homocysteine showed significant analytical performance. Our findings have implications for laboratory personnel, researchers, and physicians supporting a continuous diagnostic accuracy improvement culture.

19 February 2026 in Discover Environment
Verified
Journal Article
Open access
OGOussama Grari
Oussama Grari
AKAssya Khermach
Assya Khermach
NDNisma Douzi
Nisma Douzi
NCNouhaila Chahid
Nouhaila Chahid
AHAmina Himri
Amina Himri
RSRachid Seddik
Rachid Seddik

21 December 2023
Verified
Journal Article
Open access
OGOussama Grari
Oussama Grari
DED. Elmoujtahide
D. Elmoujtahide
ESE. Sebbar
E. Sebbar
MCM. Choukri
M. Choukri
Alzheimer's disease (AD) is the most prevalent type of dementia. Pathologically, the disease is marked by neurofibrillary tangles (NFT), which are aberrant accumulations of the tau protein that develop inside neurons, and extracellular plaque deposits of the amyloid β peptide (Aβ). These pathological lesions are present in the brain before the beginning of clinical manifestations. However, despite advancements in the comprehension of AD pathophysiology, timely and accurate clinical diagnosis remains challenging. Therefore, developing biomarkers capable of detecting AD during the preclinical phase holds enormous promise for precise diagnosis since detecting the disease early is crucial because it enables interventions when treatments may be more effective. This article intends to provide a comprehensive review of AD biomarkers, discussing their significance, classification, and recent developments in the field.

1 April 2025 in Journal of Applied Hematology
Verified
Journal Article
Open access
OGOussama Grari
Oussama Grari
AKAssya Khermach
Assya Khermach
NCNouhaila Chahid
Nouhaila Chahid
NDNisma Douzi
Nisma Douzi
AHAmina Himri
Amina Himri
RSRachid Seddik
Rachid Seddik
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm driven by the BCR::ABL1 fusion gene and typically progresses through chronic, accelerated, and blast crisis phases. While blast crises often present with myeloid or lymphoid phenotypes, transformation to acute undifferentiated leukemia (AUL) is exceedingly rare and presents significant diagnostic and therapeutic challenges. We describe a 41-year-old female with CML whose disease transformed to AUL during blast crisis. Initially treated with imatinib, therapy was discontinued due to loss of response, followed by a brief, intolerant course of nilotinib. After 2 years without treatment, she presented with general deterioration, anemia, and splenomegaly. Laboratory findings revealed hyperleukocytosis, severe thrombocytopenia, and 27% undifferentiated blasts on peripheral blood smear; bone marrow aspiration confirmed 53% blasts with negative myeloperoxidase staining. Immunophenotyping confirmed AUL, showing blasts with weak CD45 expression, CD34 positivity, HLA-DR positivity, and absence of lineage-specific markers, whereas cytogenetic analysis revealed a complex karyotype. The patient was treated with a 3 + 7 chemotherapy regimen but developed infectious complications, ultimately succumbing to cardiovascular arrest. This case highlights the complexity and poor prognosis of atypical CML transformations. It underscores the need for a deeper understanding of blast crisis mechanisms and innovative therapeutic strategies to improve patient care and outcomes.